Mon, Oct 20, 2014, 6:27 AM EDT - U.S. Markets open in 3 hrs 3 mins

Recent

% | $
Quotes you view appear here for quick access.

Yahoo! Inc. (YHOO) Message Board

left2rightdoor 75 posts  |  Last Activity: Oct 18, 2014 2:08 AM Member since: Jul 16, 2012
  • left2rightdoor by left2rightdoor Sep 24, 2014 3:06 PM Flag

    Peramivir - PDUFA date pending, Barda worried about pandemic influenza
    HAE - have a working drug, improving with second gen for once a day treatment
    BCX 4430 - a drug for more than Ebola, one drug for multiple bugs. MERs, SARS, Marburg etc. IND coming

    positioned like Auxilium for a big pharma, to add multiple pipelines.

  • Underwear For Iphone 5, Underwear For Iphone 5 Suppliers and ...
    wwwdotalibabadotcom › underwear › underwear for
    Underwear For Iphone 5, You Can Buy Various High Quality Underwear For Iphone 5 Products from Global Underwear For Iphone 5 Suppliers and Underwear For Iphone 5 ...Aibaba has just the products needed

  • South China Morning Post man found smuggling 8 iPhones in his underpants.
    (iPhone 6 plus too large.?)

  • Reply to

    Approaching...

    by maphere Sep 22, 2014 2:42 PM
    left2rightdoor left2rightdoor Sep 22, 2014 2:57 PM Flag

    Number 4 -October
    Number 3 November
    Number 2 November before number 3.

  • Solicitation Number:
    BARDA-12-100-SOL-00018
    Notice Type:
    Award Notice
    Contract Award Date:
    September 12, 2014
    Contract Award Number:
    HHSO100201400014C
    Contract Award Dollar Amount:
    Base of $65,949,445; option of $39,849,644
    Contractor Awarded Name:
    Sanofi Pasteur Inc.
    Synopsis:
    Added: Sep 17, 2014 3:00 pm
    Award is for the development of an adjuvanted pandemic influenza vaccine.

    Adjuvants never have been used or approved in US, so peramivir, which has already been used, should be even more attractive than untested adjuvants.

  • Solicitation Number:
    BARDA-12-100-SOL-00018
    Notice Type:
    Award Notice
    Contract Award Date:
    September 12, 2014
    Contract Award Number:
    HHSO100201400014C
    Contract Award Dollar Amount:
    Base of $65,949,445; option of $39,849,644
    Contractor Awarded Name:
    Sanofi Pasteur Inc.
    Synopsis:
    Added: Sep 17, 2014 3:00 pm
    Award is for the development of an adjuvanted pandemic influenza vaccine.

    Contracting Office Address:
    Office of the Assistant Secretary for Preparedness & Response (ASPR)
    Department of Health and Human Services
    330 Independence Ave. SW
    G640
    Washington, District of Columbia 20201
    United States
    Place of Performance:
    Department of Health and Human Services
    Office of the Secretary
    Acquisition Management, Contract and Grants (AMCG)
    330 Independence Avenue, G640

    Washington, District of Columbia 20201
    United States
    Primary Point of Contact.:
    Kevin Nilles,
    Contracting Officer
    kevin.nilles@hhs.gov

  • left2rightdoor left2rightdoor Sep 19, 2014 1:29 PM Flag

    Infect Disord Drug Targets. 2009 Apr;9(2):191-200.
    Drug targets in infections with Ebola and Marburg viruses.
    Gene OG1, Julia BE, Vanessa MR, Victoria WJ, Thomas GW, Lisa HE.
    Author information

    Abstract
    The development of antiviral drugs for Ebola and Marburg viruses has been slow. To date, beyond supportive care, no effective treatments, prophylactic measures, therapies, or vaccines are approved to treat or prevent filovirus infections. In this review, we examine the current treatments available to administer care for filovirus infection, the potential therapeutic targets that can be used for filovirus drug development, and the various drug targeting techniques used against filoviruses.
    PMID: 19275706 [PubMed - indexed for MEDLINE]

  • Reply to

    why is baba not trading?

    by bakhteria Sep 19, 2014 9:38 AM
    left2rightdoor left2rightdoor Sep 19, 2014 9:42 AM Flag

    The NYSE uses a human auction to set the initial price on the day of the IPO and can take between 10 and 75 minutes to determine the initial price, so around 10 it should begin to execute.

  • left2rightdoor by left2rightdoor Sep 19, 2014 3:13 AM Flag

    1. How long after 9:30 for first prices -estimate 9:45 for first price
    2. First price. 78 81 84 ?
    3 Closing price for BABA
    4 Volume traded?

  • Best guess 20-30 minutes after market opens for trading on NYSE

  • left2rightdoor left2rightdoor Sep 17, 2014 2:59 PM Flag

    Continuity of Interest
    The legal doctrine of continuity of interest underlies the principles of tax-free mergers, acquisitions, and reorganizations. Continuity of interest means that a substantial part (not strictly defined, but can vary under the facts and circumstances of the deal) of consideration received in a corporate share transaction is the acquirer's stock. The impact of this requirement is that the seller and its shareholders still have skin in the game as to the success or failure of the surviving enterprise, and are not disinterested parties which have yet realized their investment.

  • Say BABA is 85, Yahoo is 42 1 Baba for 2 Yahoo , and BABA has a. Lot of shares in its pocket, only needs 400-500 million at 2:1 would that be a taxable event for YHOO holders?

  • left2rightdoor by left2rightdoor Sep 14, 2014 10:08 AM Flag

    200 million shares?

  • Reply to

    Mid Sept. funding announcement coming? BCX4430

    by maphere Sep 8, 2014 2:00 PM
    left2rightdoor left2rightdoor Sep 10, 2014 9:17 AM Flag

    WHO fast tracks experimental drugs to fight Ebola New Scientist Sep 9
    More promising might be two wide-spectrum antiviral drugs, BCX4430 and favipiravir. Both resemble the nucleotide molecules that make up the virus's RNA genome, and fool the virus's RNA-copying enzyme – but not a human's – into using them, crippling viral replication

  • left2rightdoor left2rightdoor Sep 9, 2014 6:22 PM Flag

    There seems to be a news blackout about the Working group on experimental Ebola drugs being headed up by Asst Secty for Preparedness Dr. Nicole Lurie, ie, they don't want to indicate panic, but inside the beltway,
    at Fort Belvoir, down in Atlanta, they're in a panic. Time to batten down the hatches, and that means buy up and fund everything that might be an MCM for the EEP (Exponential Ebola Pandemic).

    From a Sep 3 story-ready to increase from 25 to 40 million.
    Mapp Biopharmaceutical has landed an 18-month, $24.9 million contract with the Department of Health and Human Services to further develop ZMapp, an antibody drug designed to treat the Ebola virus.
    HHS’ Biomedical Advanced Research and Development Authority will provide financial, preclinical and manufacturing support to Mapp with the goal of obtaining U.S. regulatory approval for the Ebola medicine, HHS said Tuesday.
    The agency says it could increase ZMapp project funding up to $42.3 million.
    “Developing drugs and vaccines to protect against Ebola as a biological threat has been a long-term goal of the U.S. government, and today’s agreement represents an important step forward,” said Dr. Nicole Lurie, HHS assistant secretary for preparedness and response.
    BARDA plans to collaborate with the National Institute of Allergy and Infectious Diseases, Defense Department and National Institutes of Health to expedite drug development.

  • FBO award Pandemic and all Hazards Preparedness - Sanofi Pasteur Sep 1.

    Solicitation Number:
    14-100-SOL-00004
    Notice Type:
    Award
    Contract Award Date:
    September 1, 2014
    Contract Award Number:
    HHSO100201400008C
    Contract Award Dollar Amount:
    42372250
    Contractor Awarded Name:
    Sanofi Pasteur, Inc.
    Contractor Awarded DUNS:
    086723285
    Contractor Awarded Address:
    1 Discovery Drive
    Swiftwater, Pennsylvania 18370
    United States

  • Reply to

    RAP-IV-AB

    by maphere Sep 2, 2014 8:40 AM
    left2rightdoor left2rightdoor Sep 7, 2014 12:39 AM Flag

    Peramivir news as single dose flu treatment from ICAAC was on CBS news on the hour and the results are all over the twitterverse among #flu site tweeters. This is all just advance prep for FDA approval.

  • Reply to

    When they lie, you should BUY

    by maphere Sep 5, 2014 11:51 AM
    left2rightdoor left2rightdoor Sep 5, 2014 2:35 PM Flag

    WHO Press release says discussed small molecule therapies. Acknowledges human safety is an unknown, but still says "intl community mobilizing to find ways to accelerate evaluation and use..." Today just a buying oppty, one order at ask only produced 100 shares. MM reluctant to sell below 12.30

    Statement on the WHO Consultation on potential Ebola therapies and vaccines

    5 September 2014

    After two days of discussion on potential Ebola therapies and vaccines, more than 150 participants, representing the fields of research and clinical investigation, ethics, legal, regulatory, financing, and data collection, identified several therapeutic and vaccine interventions that should be the focus of priority clinical evaluation at this time.

    Currently, none of these vaccines or therapies have been approved for human use to prevent or treat EVD. A number of candidate vaccines and therapies have been developed and tested in animal models and some have demonstrated promising results. In view of the urgency of these outbreaks, the international community is mobilizing to find ways to accelerate the evaluation and use of these compounds.

    Safety in humans is also unknown, raising the possibility of adverse side effects when administered. Use of some of these products is demanding and requires intravenous administration and infrastructure, such as cold chain, and facilities able to offer a good and safe standard of care.

  • left2rightdoor left2rightdoor Sep 5, 2014 2:16 PM Flag

    Materials provided by Biocryst say trials will start in SEPTEMBER with Army USAMRIID. THAT IS WITHIN NEXT 30 DAYS.

    Evidence for BCX4430 Efficacy in EBOV Infection: BCX4430 demonstrated significant efficacy, even when dosing was delayed up to 4 days after infection, in four in vivo studies in a mouse model of EBOV infection that utilizes a mouse-adapted EBOV variant. A dose-ranging study of BCX4430 in NHP experimentally infected with wild-type EBOV-Zaire is planned to start in September at US Army Medical Institute of Infectious Diseases (USAMRIID).

  •  Dr Sina Bavari, CIV US Army Medcom USA MRIID, USA

    Dr Luciana Borio, Director, Office of Counterterrorism and Emerging Threats (OCET) in the Office of the Chief Scientist, U.S. Food and Drug Administration (FDA), Rockville, USA

    Dr George Christopher, Chief Medical Officer, Joint Project Manager – Medical Countermeasure Systems, Department of Defense, Rockville, USA 

    Dr Marion Danis, Head, Section on Ethics and Health Policy, NIH, Bethesda, USA

    Dr Jesse Goodman, George Town University, Washington, USA

    Dr Barney Graham, Vaccine Research Centre, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA

    Dr Fred Hayden, University of Virginia/WHO consultant, Charlottesville, USA

    Dr Lisa Hensley, National Institute of Allergy and Infectious Diseases, NIH , Bethesda, USA 

    Dr Elizabeth Higgs, Global Health Science Advisor, Office of the Director, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA 

    Dr David Hone, Chief, Vaccine Branch, Research and Development Directorate (J9), Defense Threat Reduction Agency (DTRA), Department of Defense, Fort Belvoir, USA

    Dr Franca Jones, Medical Director, Chemical and Biological Defense Program, Office of the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs OASD(NCB/CB), Rockville, USA

    Dr Christopher Karp, Deputy Director, Discovery and Translational Sciences, Bill & Melinda Gates Foundation, Seattle, USA 

     Dr Steve Kern, Deputy Director, Integrated Development, Bill & Melinda Gates Foundation, Seattle, USA

    Dr Michael Kurilla, Director, Office of BioDefense, Research Resources, and Translational Research, Associate Director for BioDefense Product Development, NIAID, NIH, Rockville, USA

    Dr Mike Levine, Director, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, USA 

    Dr Nicole Lurie, Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services, Washington, USA

    Dr Eric Mast, Deputy Director Science and Research, Center for Disease Control and Prevention, Atlanta, USA

    Dr Robin Robinson, Director, Biomedical Advanced Research & Development Authority, US Department of Health and Human Services, Washington, USA

    Dr Kacey Wulff, Special Assistant to the Assistant Secretary of Preparedness and Response, US Department of Health and Human Services, Washington, USA

YHOO
38.45+0.43(+1.12%)Oct 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
NewLink Genetics Corporation
NasdaqGMFri, Oct 17, 2014 4:00 PM EDT
SAP SE
NYSEFri, Oct 17, 2014 4:02 PM EDT